Page 7 - Guide de pratique de l’Association des urologues du Canada pour le suivi des patients après le traitement d’un carcinome à cellules rénales non métastatique

Guide de pratique : Suivi du CCR non métastatique

participé à des conseils consultatifs pour AbbVie, Amgen, Astellas, Bayer, Janssen, Roche et Sanofi. Le 19. Skolarikos A, Alivizatos G, Laguna P, et al. A review on followup strategies for renal cell carcinoma after
D Kapoor a participé à des conseils consultatifs pour Amgen, Astellas, GSK, Janssen, Novartis, Pfizer nephrectomy. Eur Urol 2007;51:1490-500. https://doi.org/10.1016/j.eururo.2006.12.031
r
et Sanofi, et a participé à des essais cliniques parrainés par ces mêmes compagnies. Le D Lattouf a 20. University of Oxford, Graduate School in EBM and Research Methods, Centre for Evidence-based Medicine
r
participé à des conseils consultatifs pour AbbVie, Amgen, Astellas, Novartis et Pfizer; et a reçu une – Levels of Evidence 2009. Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon
subvention à visée éducative de Janssen. Le D Leveridge a participé à des conseils consultatifs pour Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009.
r
Astellas. Le D Power a participé à des essais cliniques parrainés par Argos Therapeutics. Le D Pouliot http://www.cebm.net/index.aspx?o=1025. Accessed July 1, 2017.
r
r
a participé à des conseils consultatifs pour Amgen, Astellas et Pfizer; a agi à titre de conférencier pour 21. Kates M, Badalato GM, McKiernan JM. Renal functional outcomes after surgery for renal cortical tumours.
Curr Opin Urol 2011;21:351-5. https://doi.org/10.1097/MOU.0b013e32834962e9
Sanofi; a reçu des subventions et honoraires d’Amgen, Astellas, AstraZeneca, Janssen, Pfizer et Sanofi. 22. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risk of death, cardiovascular events,
Le D So a agi à titre de conférencier pour Amgen, Astellas et Janssen. Le D Tanguay a participé à des and hospitalization. N Engl J Med 2004;351:1296-305. https://doi.org/10.1056/NEJMoa041031
r
r
conseils consultatifs pour Pfizer, et a reçu des subventions de voyage de Sanofi. Les autres auteurs 23. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for
n’ont aucun conflit d’intérêts personnels ou financiers à déclarer relativement au présent document. the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35. https://doi.org/10.1053/j.
ajkd.2014.01.416
24. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal
Cet article a été révisé par un comité de lecture. cortical tumours: A retrospective cohort study. Lancet Oncol 2006;7:735-40. https://doi.org/10.1016/
S1470-2045(06)70803-8
25. Mashni JW, Assel M, Maschino A, et al. New chronic kidney disease and overall survival after neph-
rectomy for small renal cortical tumours. Urology 2015;86:1137-43. https://doi.org/10.1016/j.
Références urology.2015.07.046
26. Clark MA, Shikanov S, Raman JD, et al. Chronic kidney disease before and after partial nephrectomy. J
Urol 2011;185:43-8. https://doi.org/10.1016/j.juro.2010.09.019
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 27. Rendon RA, Mason R, Kapoor A, et al. The natural history of renal function after surgical manage-
https://doi.org/10.3322/caac.21332 ment of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. Urol Oncol
2. Lucca I, Klatte T, Fajkovic H, et al. Gender differences in incidence and outcomes of urothelial and kidney 2016;34:486.e1-7. https://doi.org/10.1016/j.urolonc.2016.05.025
cancer. Nat Rev Urol 2015;12:585-92. https://doi.org/10.1038/nrurol.2015.232 28. Chung JS, Son NH, Byun SS, et al. Trends in a renal function after radical nephrectomy: A multicentre
3. Qayyum T, Oades G, Horgan P, et al. The epidemiology and risk factors for renal cancer. Curr Urol analysis. BJU Int 2014;113:408-15. https://doi.org/10.1111/bju.12277
2013;6:169-74. https://doi.org/10.1159/000343534 29. Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology
4. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol clinical practice guideline. J Clin Oncol 2017;35:668-80. https://doi.org/10.1200/JCO.2016.69.9645
2010;7:245-57. https://doi.org/10.1038/nrurol.2010.46 30. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of
5. Macleod LC, Hotaling JM, Wright JL, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: A collabora-
2013;190:1657-61. https://doi.org/10.1016/j.juro.2013.04.130 tive meta-analysis of general population cohorts: A collaborative meta-analysis. Lancet 2010;375:2073-
6. Sanfilippo KM, McTigue KM, Fidler CJ, et al. Hypertension and obesity and the risk of kidney cancer in 81. https://doi.org/10.1016/S0140-6736(10)60674-5
two large cohorts of U.S. men and women. Hypertension 2014;63:934-41. https://doi.org/10.1161/ 31. Pettus JA, Jang TL, Thompson RH, et al. Effect of baseline glomerular filtration rate on survival in patients
HYPERTENSIONAHA.113.02953 undergoing partial or radical nephrectomy for renal cortical tumours. Mayo Clin Proc 2008;83:1101-6.
7. Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis https://doi.org/10.4065/83.10.1101
1995;26:1-12. https://doi.org/10.1016/0272-6386(95)90146-9 32. Brenner DJ, Hall EJ. Computed tomography — an increasing source of radiation exposure. N Engl J Med
8. Mariusdottir E, Ingimarsson JP, Jonsson E, et al. Occupation as a risk factor for renal cell cancer: A 2007;357:2277-84. https://doi.org/10.1056/NEJMra072149
nationwide, prospective, epidemiological study. Scan J Urol 2016;50:181-5. https://doi.org/10.31 33. Chang SL, Cipriano LE, Harshman LC, et al. Cost-effectiveness analysis of nephron-sparing options for
09/21681805.2016.1151460 the management of small renal masses. J Urol 2011;185:1591-7. https://doi.org/10.1016/j.
9. Karami S, Boffetta P, Stewart PS, et al. Occupational exposure to dusts and risk of renal cell carcinoma. juro.2010.12.100
Br J Cancer 2011;104:1797-803. https://doi.org/10.1038/bjc.2011.148 34. Marconi L, Gorin MA, Allaf ME. Post-partial nephrectomy surveillance imaging: An evidence-based approach.
10. Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol 2015;132:139-56. Curr Urol Rep 2015;16:23. https://doi.org/10.1007/s11934-015-0489-7
https://doi.org/10.1016/B978-0-444-62702-5.00010-X 35. Lipsky MJ, Shapiro EY, Hruby GW, et al. Diagnostic radiation exposure during surveillance in patients with
11. Yap NY, Rajandram R, Ng KL, et al. Genetic and chromosomal aberrations and their clinical significance pT1a renal cell carcinoma. Urology 2013;81:1190-5. https://doi.org/10.1016/j.urology.2012.08.056
in renal neoplasms. Biomed Res Int 2015;2015:476508. https://doi.org/10.1155/2015/476508 36. Zargar-Shoshtari K, Kim T, Simon R, et al. Surveillance following nephron-sparing surgery: An assessment
12. Adeniran AJ, Shuc B, Humphrey PA. Hereditary renal cell carcinoma syndromes: Clinical, patho- of recurrence patterns and surveillance costs. Urology 2015;86:321-6. https://doi.org/10.1016/j.
logical, and genetic features. Am J Surg Pathol 2015;39:e1-e18. https://doi.org/10.1097/ urology.2015.05.013
PAS.0000000000000562 37. Bani-Hani AH, Leibovich BC, Loshe CM, et al. Associations with contralateral recurrence following
13. Linehan WM. Genetic basis of kidney cancer: Role of genomics for the development of disease-based nephrectomy for renal cell carcinoma using a cohort of 2352 patients. J Urol 2005;173:391-4.
therapeutics. Genome Res 2012;22:2089-100. https://doi.org/10.1101/gr.131110.111 https://doi.org/10.1097/01.ju.0000148951.71353.8b
14. Byler TK, Bratslavsky G. Hereditary renal cell carcinoma: Genetics, clinical features, and surgical considera- 38. Chow JJ, Ahmed K, Fazili Z, et al. Solitary renal fossa recurrence of renal cell carcinoma after nephrectomy.
tions. World J Urol 2014;32:623-30. https://doi.org/10.1007/s00345-014-1287-4 Rev Urol 2014;16:76-82.
15. Zini L, Perrotte P, Jeldres C, et al. A population-based comparison of survival after nephrectomy vs. non- 39. Thomas AZ, Adibi M, Borregales LD, et al. Surgical management of local retroperitoneal recurrence of
surgical management for small renal masses. BJU Int 2009;103:899-904. https://doi.org/10.1111/ renal cell carcinoma after radical nephrectomy. J Urol 2015;194:316-22. https://doi.org/10.1016/j.
j.1464-410X.2008.08247.x juro.2015.02.2943
16. Pierorazio PM, Johnson MH, Patel HD, et al. Management of renal masses and localized renal can- 40. Kapoor A, Bansal RK, Tanguay S, et al. Positive surgical margins during partial nephrectomy for renal
cer: Systematic review and meta-analysis. J Urol 2016;196:989-99. https://doi.org/10.1016/j. cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. Can Urol
juro.2016.04.081 Assoc J 2017;11:182-7. https://doi.org/10.5489/cuaj.4264
17. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study 41. Psutka SP, Heidenreich M, Boorjian SA, et al. Renal fossa recurrence after nephrectomy for
comparing the oncological outcome of elective nephron-sparing surgery and radical nephrectomy for low- renal cell carcinoma: Prognostic features and oncological outcomes. BJU Int 2017;119:116-27.
stage renal cell carcinoma. Eur Urol 2011;59:543-52. https://doi.org/10.1016/j.eururo.2010.12.013 https://doi.org/10.1111/bju.13620
18. Tan HJ, Norton EC, Ye Z, et al. Long-term survival following partial vs. radical nephrectomy among 42. Paparel P, Bigot P, Matillon X, et al. Local recurrence after radical nephrectomy for kidney cancer:
older patients with early-stage kidney cancer. JAMA 2012;307:1629-35. https://doi.org/10.1001/ Management and prediction of outcomes. A multi-institutional study. J Surg Oncol 2014;109:126-31.
jama.2012.475 https://doi.org/10.1002/jso.23473

CUAJ • Août 2018 • Volume 12, numéro 8 R87